Cecelia Cropp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cecelia Cropp has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Diggs
Department of Biology, College of Arts & Sciences, American University, Washington, DC 20016, USA
2 shared publications - Alexander George Zestos
American University
2 shared publications - Anthony L. Riley
Psychopharmacology Laboratory, Department of Neuroscience, Center for Neuroscience and Behavior, American University, Washington, D.C., 20016, USA
2 shared publications - Cailyn Sullivan
Department of Biology, College of Arts & Sciences, American University, Washington, DC 20016, USA
2 shared publications - Coco Izumi
Department of Biology, College of Arts & Sciences, American University, Washington, DC 20016, USA
2 shared publications - Dacia Marquez
Department of Biology, College of Arts & Sciences, American University, Washington, DC 20016, USA
2 shared publications
Latest Publications
- Open Access
- 13 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6724
Oxidative Stress in HIV-Associated Neurodegeneration: Mechanisms of Pathogenesis and Therapeutic Targets
Treatment for HIV infection has become more manageable due to advances in combination antiretroviral therapy (cART). However, HIV still significantly affects the central nervous system (CNS) in infected individuals, even with effective plasma viral suppression, due to persistent viral reservoirs and chronic neuroinflammation. This ongoing inflammation contributes to the development of HIV-associated neurocognitive disorders (HANDs), including dementia and Alzheimer’s disease-like pathology. These complications are particularly prevalent among the aging population with HIV. This review aims to provide a comprehensive overview of HAND, with a focus on the contribution of oxidative stress induced by HIV-mediated reactive oxygen species (ROS) production through viral proteins such as gp120, Tat, Nef, Vpr, and reverse transcriptase. In addition, we discuss current and emerging therapeutic interventions targeting HAND, including antioxidant strategies and poly (ADP-ribose) polymerase (PARP) inhibitors. These are potential adjunctive approaches to mitigate neuroinflammation and oxidative damage in the CNS.
- 13 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6724
Open AccessOxidative Stress in HIV-Associated Neurodegeneration: Mechanisms of Pathogenesis and Therapeutic Targets
Treatment for HIV infection has become more manageable due to advances in combination antiretroviral therapy (cART). However, HIV still significantly affects the central nervous system (CNS) in infected individuals, even with effective plasma viral suppression, due to persistent viral reservoirs and chronic neuroinflammation. This ongoing inflammation contributes to the development of HIV-associated neurocognitive disorders (HANDs), including dementia and Alzheimer’s disease-like pathology. These complications are particularly prevalent among the aging population with HIV. This review aims to provide a comprehensive overview of HAND, with a focus on the contribution of oxidative stress induced by HIV-mediated reactive oxygen species (ROS) production through viral proteins such as gp120, Tat, Nef, Vpr, and reverse transcriptase. In addition, we discuss current and emerging therapeutic interventions targeting HAND, including antioxidant strategies and poly (ADP-ribose) polymerase (PARP) inhibitors. These are potential adjunctive approaches to mitigate neuroinflammation and oxidative damage in the CNS.
- Open Access
- 11 June 2025
- Published by MDPI AG in Preprints.org
Oxidative Stress in HIV-Associated Neurodegeneration: Mechanisms of Pathogenesis and Therapeutic Targets
Treatment for HIV infection has become more manageable due to advances in combination antiretroviral therapy (cART). However, it still significantly affects the central nervous system (CNS) in HIV-infected individuals, even with effective plasma viral suppression, due to persistent viral reservoirs and chronic neuroinflammation. This ongoing inflammation contributes to the development of HIV-associated neurocognitive disorders (HAND), including dementia and Alzheimer's disease-like pathology. These complications are particularly prevalent among the aging population with HIV. This review aims to provide a comprehensive overview of HAND, with a focus on the contribution of oxidative stress induced by HIV-mediated reactive oxygen species (ROS) production through viral proteins such as gp120, Tat, Nef, Vpr, and Reverse Transcriptase. In addition, we discuss current and emerging therapeutic interventions targeting HAND, including antioxidant strategies and poly(ADP-ribose) polymerase (PARP) inhibitors. These are potential adjunctive approaches to mitigate neuroinflammation and oxidative damage in the CNS.
- 11 June 2025
- Published by MDPI AG in Preprints.org
Open AccessOxidative Stress in HIV-Associated Neurodegeneration: Mechanisms of Pathogenesis and Therapeutic Targets
Treatment for HIV infection has become more manageable due to advances in combination antiretroviral therapy (cART). However, it still significantly affects the central nervous system (CNS) in HIV-infected individuals, even with effective plasma viral suppression, due to persistent viral reservoirs and chronic neuroinflammation. This ongoing inflammation contributes to the development of HIV-associated neurocognitive disorders (HAND), including dementia and Alzheimer's disease-like pathology. These complications are particularly prevalent among the aging population with HIV. This review aims to provide a comprehensive overview of HAND, with a focus on the contribution of oxidative stress induced by HIV-mediated reactive oxygen species (ROS) production through viral proteins such as gp120, Tat, Nef, Vpr, and Reverse Transcriptase. In addition, we discuss current and emerging therapeutic interventions targeting HAND, including antioxidant strategies and poly(ADP-ribose) polymerase (PARP) inhibitors. These are potential adjunctive approaches to mitigate neuroinflammation and oxidative damage in the CNS.